Abstract
Our study was designed to prospectively determine whether or not unrelated cord blood transplantation (CBT) can produce outcomes comparable to related donor transplantation for children with β-thalassaemia. In 35 patients, 40 transplants were performed between October 2003 and September 2009. HLA matching at enrolment was 6/6 (n=8), 5/6 (n=16), 4/6 (n=27), or 3/6 (n=1) by low-resolution HLA-A, -B, and high-resolution DRB1. These patients received non-manipulated grafts without ex vivo expansion or T-cell depletion. The median number of nucleated and CD34+ cells infused was 7.8 × 107/kg (range, 2.8–14.7 × 107/kg) and 4.0 × 105/kg (range, 1.7–19.9 × 105/kg), respectively. The 5-year OS and thalassaemia-free survival after the first transplant were 88.3 and 73.9%, respectively. The cumulative incidence of TRM at 2 years was 11.7%. Fourteen patients developed chronic skin GVHD. Thirty patients were alive and transfusion-independent with a Lansky performance score ⩾80% achieved between 6 and 76 months post transplant (median, 36 months). These data compare acceptably with the survival rates of related-donor BMT for thalassaemia and suggest that patients without an available HLA-compatible sibling but who have well-matched unrelated donors should also be considered for CBT.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Modell B, Darlison M . Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008; 86: 480–487.
Weatherall DJ, Clegg JB . Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ 2001; 79: 704–712.
Angastiniotis M, Modell B, Englezos P, Boulyjenkov V . Prevention and control of haemoglobinopathies. Bull World Health Organ 1995; 73: 375–386.
Prasad VK, Kurtzberg J . Umbilical cord blood transplantation for non-malignant diseases. Bone Marrow Transplant 2009; 44: 643–651.
Neufeld EJ . Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006; 107: 3436–3441.
Wagner JE, Barker JN, DeFor TE, Barker KS, Blazar BR, Eide C et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100: 1611–1618.
Benito AI, Diaz MA, Gonzalez-Vicent M, Sevilla J, Madero L . Hematopoietic stem cell transplantation using umbilical cord blood progenitors: review of current clinical results. Bone Marrow Transplant 2004; 33: 675–690.
Morris CR, Singer ST, Walters MC . Clinical hemoglobinopathies: iron, lungs and new blood. Curr Opin Hematol 2006; 13: 407–418.
Angelucci E, Baronciani D . Allogeneic stem cell transplantation for thalassemia major. Haematologica 2008; 93: 1780–1784.
Seghatchian J, Solheim BG . Current opinions on safer red cell transfusion practice and the appropriate use of alternative strategies. Transfus Apher Sci 2007; 37: 201–207.
Rubinstein P, Dobrila L, Rosenfield RE, Adamson JW, Migliaccio G, Migliaccio AR et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci 1995; 92: 10119–10122.
Cappellini MD, Piga A . Current status in iron chelation in hemoglobinopathies. Curr Mol Med 2008; 8: 663–674.
Cazzola M, Borgna-Pignatti C, Locatelli F, Ponchio L, Beguin Y, De Stefano P . A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis. Transfusion 1997; 37: 135–140.
Locatelli F, Rocha V, Reed W, Bernaudin F, Ertem M, Grafakos S et al. Related umbilical cord blood transplantation in patients with thalassemia and sickle cell disease. Blood 2003; 101: 2137–2143.
Lucarelli G, Galimberti M, Giardini C, Polchi P, Angelucci E, Baronciani D et al. Bone marrow transplantation in thalassemia. The experience of Pesaro. Ann N Y Acad Sci 1998; 850: 270–275.
Hongeng S, Pakakasama S, Chuansumrit A, Sirachainan N, Kitpoka P, Udomsubpayakul U et al. Outcomes of transplantation with related- and unrelated-donor stem cells in children with severe thalassemia. Biol Blood Marrow Transplant 2006; 12: 683–687.
Resnick IB, Aker M, Tsirigotis P, Shapira MY, Abdul-Hai A, Bitan M et al. Allogeneic stem cell transplantation from matched related and unrelated donors in thalassemia major patients using a reduced toxicity fludarabine-based regimen. Bone Marrow Transplant 2007; 40: 957–964.
Locatelli F, De Stefano P . Innovative approaches to hematopoietic stem cell transplantation for patients with thalassemia. Haematologica 2005; 90: 1592–1594.
Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945–955.
Couriel D, Carpenter P, Cutler C, Bolaños-Meade J, Treister NS, Gea-Banacloche J et al. Ancillary therapy and supportive care of chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant 2006; 12: 375–396.
O’Brien T, Eastlund T, Peters C, Neglia JP, Defor T, Ramsay NK et al. Autoimmune haemolytic anemia complicating haematopoietic cell transplantation in paediatric patients: high incidence and significant mortality in unrelated transplants for non-malignant disease. Br J Haematol 2004; 127: 67–75.
Page KM, Mendizabal AM, Prasad VK, Martin PL, Parikh S, Wood S et al. Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation. Biol Blood Marrow Transplant 2008; 14: 1108–1117.
Bachar-Lustig E, Rachamim N, Li HW, Lan F, Reisner Y . Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995; 1: 1268–1273.
Brunstein CG, Wagner JE . Umbilical cord blood transplantation and banking. Annu Rev Med 2006; 57: 403–417.
Kurtzberg J . Update on umbilical cord blood transplantation. Curr Opin Pediatr 2009; 21: 22–29.
Brown JA, Boussiotis VA . Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution. Clin Immunol 2008; 127: 286–297.
Gaziev J, Sodani P, Polchi P, Andreani M, Lucarelli G . Bone marrow transplantation in adults with thalassemia: treatment and long-term follow-up. Ann N Y Acad Sci 2005; 1054: 196–205.
Locatelli F, Stefano PD . New insights into haematopoietic stem cell transplantation for patients with haemoglobinopathies. Br J Haematol 2004; 125: 3–11.
Cheuk DK, Mok AS, Lee AC, Chiang AK, Ha SY, Lau YL et al. Quality of life in patients with transfusion-dependent thalassemia after hematopoietic SCT. Bone Marrow Transplant 2008; 42: 319–327.
Acknowledgements
We are indebted to the patients and their carers for participating in the externally audited results. The authors acknowledge and thank the Department of Health, Executive Yuan in Taiwan, for helping to conduct and supervise the clinical trial of cord blood transplantation. This work was supported by grant CMRPG4A0031 from the Chang Gung Medical Research Program.
The material contained in this paper has been presented at the following meetings:
1. Jaing TH, Wang B, Gjertson D, Law P, Petz L, Chow R. Unrelated Cord Blood Transplantation (UCBT) for Transfusion-Dependent Thalassemia a CIBMTR Audited Retrospective Analysis of 30 Consecutive Patients from a Single Center. Session Type: Oral Session, Board #131. 50th ASH annual meeting; San Francisco, CA, USA; 6–9 December 2008.
2. Jaing TH, Wang B, Gjertson D, Law P, Petz L, Chow R. Unrelated Cord Blood Transplantation (UCBT) for Transfusion-Dependent Thalassemia a CIBMTR Audited Retrospective Analysis of 30 Consecutive Patients from a Single Center. CIBMTR 2009 BMT Tandem Meeting; Tampa, Florida, USA; 11–15 February 2009.
3. Jaing TH. Transplantation of Patients with Transfusion-dependent Thalassemia. 8th Annual International Cord Blood Transplantation Symposium: San Francisco, CA, USA; 3–5 June 2010.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors indicated no potential conflicts of interest. No honorarium or payment of expenses was given to authors to produce the paper.
Rights and permissions
About this article
Cite this article
Jaing, TH., Hung, IJ., Yang, CP. et al. Unrelated cord blood transplantation for thalassaemia: a single-institution experience of 35 patients. Bone Marrow Transplant 47, 33–39 (2012). https://doi.org/10.1038/bmt.2011.39
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2011.39
Keywords
This article is cited by
-
Hematopoietic stem cell transplantation for children with β-thalassemia major: multicenter experience in China
World Journal of Pediatrics (2018)